<DOC>
	<DOCNO>NCT02065765</DOCNO>
	<brief_summary>The treat physician/investigator contact Lilly , base medical opinion , patient meet criteria inclusion compassionate use program .</brief_summary>
	<brief_title>International Expanded Access Program Provide Ramucirumab Treatment Metastatic Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Ramucirumab</mesh_term>
	<criteria>The participant histologically cytologically confirm gastric carcinoma , include gastric adenocarcinoma gastroesophageal junction ( GEJ ) adenocarcinoma . ( Participants adenocarcinoma distal esophagus eligible primary tumor involve GEJ ) The participant metastatic disease locally recurrent , unresectable disease The participant measureable evaluable disease determine standard compute tomography ( CT ) magnetic resonance imaging ( MRI ) imaging . Examples evaluable , nonmeasurable disease include gastric , peritoneal , mesenteric thicken area know disease , peritoneal nodule small consider measurable Response Evaluation Criteria Solid Tumors ( RECIST version 1.1 ) The participant experience disease progression treatment within 4 month last dose firstline therapy metastatic disease , treatment , within 6 month last dose adjuvant therapy Acceptable prior chemotherapy regimen protocol combination chemotherapy regimens include platinum and/or fluoropyrimidine component . Regimens include third agent , anthracycline taxane , acceptable provide fluoropyrimidine and/or platinum use . The participant resolution Grade ≤1 ( Grade ≤2 case neuropathy ) National Cancer Institute Common Terminology Criteria Adverse Events ( NCICTCAE ) , Version 4.03 , clinically significant toxic effect prior chemotherapy , surgery , radiotherapy , hormonal therapy ( exception alopecia ) The participant Eastern Cooperative Oncology Group performance status ( ECOG PS ) score 0 1 The participant adequate hepatic function The participant : cirrhosis level ChildPugh B ( bad ) cirrhosis ( degree ) history hepatic encephalopathy clinically meaningful ascites result cirrhosis . Clinically meaningful ascites define ascites cirrhosis require diuretic paracentesis The participant adequate renal function define serum creatinine ≤1.5 time upper limit normal ( ULN ) , creatinine clearance ( measure via 24hour urine collection ) ≥40 milliliter per minute ( mL/minute ) The participant 's urinary protein ≤1+ dipstick routine urinalysis ( UA ) The participant adequate hematologic function The participant must adequate coagulation function If participant receive prior anthracycline therapy part firstline regimen , participant able engage ordinary physical activity without significant fatigue dyspnea ( equivalent New York Heart Association Class I function ) Because teratogenicity ramucirumab know , participant , sexually active , must postmenopausal , surgically sterile , use effective contraception ( hormonal barrier method ) Female participant childbearing potential must negative serum pregnancy test within 7 day prior enrollment The participant document and/or symptomatic brain leptomeningeal metastases The participant experience Grade 3 4 gastrointestinal ( GI ) bleed within 3 month prior enrollment The participant experience arterial thromboembolic event , include limited myocardial infarction , transient ischemic attack , cerebrovascular accident , unstable angina , within 6 month prior enrollment The participant ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , symptomatic poorly control cardiac arrhythmia , uncontrolled thrombotic hemorrhagic disorder , serious uncontrolled medical disorder opinion treat physician The participant ongoing active psychiatric illness social situation would limit compliance treatment The participant uncontrolled poorly control hypertension [ &gt; 160 milliliter mercury ( mmHg ) systolic &gt; 100 mmHg diastolic &gt; 4 week ] despite standard medical management The participant serious nonhealing wound , ulcer , bone fracture within 28 day prior enrollment The participant receive chemotherapy , radiotherapy , immunotherapy , target therapy gastric cancer within 2 week prior enrollment The participant receive investigational therapy within 30 day prior enrollment The participant undergone major surgery within 28 day prior enrollment , subcutaneous venous access device placement within 7 day prior enrollment The participant receive prior therapy agent directly inhibit vascular endothelial growth factor ( VEGF ) ( include bevacizumab ) , vascular endothelial growth factor receptor2 ( VEGFR2 ) activity , antiangiogenic agent The participant receive chronic antiplatelet therapy , include aspirin , nonsteroidal antiinflammatory drug ( NSAIDs ; include ibuprofen , naproxen , others ) , dipyridamole clopidogrel , similar agent . Oncedaily aspirin use ( maximum dose 325 mg/day ) permit The participant elective plan major surgery perform course clinical trial The participant know allergy treatment component The participant pregnant breastfeed The participant know positive infection human immunodeficiency virus ( HIV ) The participant know alcohol drug dependency The participant concurrent active malignancy adequately treat nonmelanomatous skin cancer , noninvasive carcinoma , situ neoplasm The participant know hypersensitivity ramucirumab excipients The patient may receive 1 prior therapy metastatic setting .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>